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Abstract Twenty patients with chronic inflammatory demyelinating polyradiculoneu-
ropathy (CIDP) meeting the EFNS/PNS criteria were examined in order to assess
differences/similarities between the various grading systems according to CIDP disease
activity status (CDAS). A principal component (PC) analysis and the correlations between
the following scores were performed: Neurological Symptom Score; MRC sum score;
Neurological Impairment Score; Hammersmith Functional Motor Scale; Inflammatory Neu-
ropathy Cause and Treatment (INCAT) Sensory Sum Score; Overall Disability Sum Score;
INCAT Disability Score; Rasch-built Overall Disability Scale. Our analysis outlined two main
sets of scales, with high influence in the top two PCs. The first PC that best explained
the variability within the cohort consisted of CDAS, general disability scores and motor
scores; these parameters were also strongly correlated amongst each other. The second
PC explained less the variability and consisted mainly of sensory scores and disease dura-
tion; these parameters did not correlate with the scores of the first PC or with the CDAS.
Our findings suggest separating screening for motor and sensory deficits when evaluating
CIDP patients, as only the motor scores correlate with CDAS.
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Introduction
Chronic inflammatory demyelinating polyradicu-
loneuropathy (CIDP) is an autoimmune neuropathy
with high clinical heterogeneity leading to various
degrees of disability. Expert consensus is available for
diagnosis and treatment (Joint Task Force of the EFNS
and the PNS, 2010). For diagnosis and assessment of
treatment effectiveness, a series of grading systems
have been proposed by the Inflammatory Neuropathy
Cause and Treatment (INCAT) group and others:
(1) general disability scores, such as Neurological
Address correspondence to: Dr. Thierry Kuntzer, Department of
Clinical Neurosciences, Nerve-Muscle Unit, CHUV, Rue du Bugnon
46, 1011 Lausanne, Switzerland. Tel: +41-21-314-12-91; Fax: +41-
21-314-12-56; E-mail: thierry.kuntzer@chuv.ch
Impairment Score (Dyck et al., 1980), Neurological
Symptom Score (Dyck et al., 1980), INCAT Disability
Score (Hughes et al., 2001), INCAT Overall Disability
Sum Score (Merkies et al., 2002) or the Rasch-built
Overall Disability Scale (van Nes et al., 2011); (2) motor
scores, such as Medical Research Council Sum Score
(Dyck et al., 2005), Hammersmith Functional Motor
Scale (Scott et al., 1982) and motor component of
NIS; (3) sensory scores, such as INCAT Sensory Sum
Score (Merkies et al., 2000) or the sensory component
of NIS. Recently, a grading system assessing disease
activity in relation to treatment status, the CIDP
disease activity status (CDAS) (Gorson et al., 2010),
has been developed to complement the disability and
impairment scales and is applicable in both clinical
practice and research studies.
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Our goal is to analyze a series of CIDP patients
using current clinical scores, to establish a relationship
between scores and to examine correlations of the
scores with CDAS.
Patients and Methods
Patients
Twenty-five patients fulfilling the EFNS/PNS
criteria for CIDP were contacted to participate in this
study. Twenty agreed to take part in this study and
provided informed consent. This study was approved
by the hospital’s ethics committee.
Assessed scales
Between May and December 2011, every
patient underwent a neurological examination by two
investigators. The following grading systems were
evaluated:
General scores and scales:
1 Neurological Symptom Score (NSS) (Dyck et al.,
1980; Herndon, 2005).
2 Neurological Impairment Score (NIS) (Dyck et al.,
1980).
3 Inflammatory Neuropathy Cause and Treatment
Group (INCAT) Overall Disability Sum Score (ODSS)
(Merkies et al., 2002).
4 INCAT Disability Score (INCAT DS) (Hughes et al.,
2001).
Motor scores:
1 Hammersmith Functional Motor Scale (HFMS)
(Scott et al., 1982).
2 Medical Research Council Sum Score (MRC) (Dyck
et al., 2005).
3 Rasch-built Overall Disability Scale (R-ODS) (van Nes
et al., 2011).
Sensory score:
1 The INCAT Sensory Sum Score (ISS) (Merkies et al.,
2000).
The CIDP disease activity status (CDAS)
(Standard CDAS, see Table 1)
We intended to assess the relationship between
CDAS and the clinical grading systems. However, the
categories 1 to 4 in CDAS each include a subcategory
for patients with normal examination. Therefore, in
order to make valid comparisons, we modified the
CDAS (Modified CDAS, see Table 1), pooling the
subcategories of patients with normal examination as
0; the remaining subcategories are distributed from 1
to 7 in the following order: 1-cured (1B in standard
Table 1. Proposed modified numerical version of CDAS.
Standard CDAS Modified CDAS
1. Cured: ≥5 years off treatment
A. Normal examination 0
B. Abnormal examination,
stable/improving
1
2. Remission: <5 years off treatment
A. Normal examination 0
B. Abnormal examination,
stable/improving
2
3. Stable active disease: ≥1 year on
treatment
A. Normal examination 0
B. Abnormal examination,
stable/improving
3
4. Improvement: ≥3 months <1 year on
treatment
A. Normal examination 0
B. Abnormal examination,
stable/improving
4
5. Unstable active disease: abnormal
examination with progressive or
relapsing course
A. Treatment naı¨ve or <3 months 5
B. Off treatment 6
C. On treatment 7
The different subcategories of CDAS were renumbered on a
numerical scale, with 0 for asymptomatic patients and distributing
the other subcategories with abnormal examination from 1 to 7.
CDAS, chronic inflammatory demyelinating polyradiculoneuropathy
disease activity status.
CDAS), 2-in remission (2B), 3-stable active disease
(3B), 4-improving (4B), and 5-unstable active disease
with naı¨ve treatment (5A), 6-off treatment (5B), or 7-on
treatment (5C).
Statistics
The data obtained for each evaluated scale was
checked for normality and transformations were
applied when necessary. Using JMP 10.0 statistical
software (SAS Institute Inc., Cary, NC, USA) we
performed a principal component analysis (PCA) on
correlations on the group of evaluated scales and
patient characteristics. PCA visualizes the structure
of a data set as completely as possible using
as few variables as possible. It derives a small
number of independent linear combinations (principal
components, PCs) of a set of variables, capturing
as much of the variability in the original variables
as possible. When analyzing a number of original
variables, an equal number of PCs uncorrelated with
each other is formed, in decreasing order of greatest
possible variance (SAS Institute Inc., 2012). The
Pearson’s correlations for the assessed variable were
also calculated by JMP 10.0 statistical software as a
by-product of the PCA, and were analyzed for a more
in depth view of the PCA results.
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Table 2. Clinical characteristics of the studied cohort
(n=20 patients).
Age (years)
<40 15%
40–65 45%
65+ 40%
Male gender 70%
Caucasian 100%
History of spontaneous relapses 25%
Symmetric onset 90%
Sensory symptoms
None 10%
Asymmetric 5%
Both sides 85%
Facial weakness 0%
Symmetric on motor exam 95%
Distal weakness on exam
No limbs 55%
1–3 limbs 30%
All four limbs 15%
Proximal weakness on exam
None 55%
1–3 limbs 25%
All four limbs 15%
Number of absent/hypoactive reflexes
None 5%
1–9 35%
All 10 60%
Abnormal sensory function
No 10%
Asymmetric 5%
Symmetric 90%
Evidence of demyelination on biopsy
Biopsy not done 90%
No 0%
Yes 10%
Evidence of axon loss on biopsy
No 0%
Yes 10%
CSF protein (mg/dl)
≤45 15%
>45 65%
Not tested/data not available 20%
CSF cells (number/μl)
<10 80%
≥10 0%
Not tested/data not available 20%
Results
Cohort clinical characteristics
The group of patients consisted of 14 men and 6
women who had a mean duration of symptoms of 5.9
years. None of the patients had normal examination;
one was bed-bound while another required crutches
to walk short distances. Fifty percent of the patients
had stable active disease, 35% were in remission,
10% were unstable with active disease and 5%
were improving. A summary of the clinical features
is provided in Table 2 and an overview of the grading
system results is in Table 3.
Table 3. Results of the evaluated grading systems.
Average (range) Normal value
ISS 3.1 (1–7) 0
NSS 3.5 (1–8) 0
S-NIS 7.8 (1–16) 0
M-NIS 9.6 (0–52) 0
HFMS 34.7 (10–40) 40
MRC 55.7 (44–60) 60
NIS 29.2 (2–80) 0
ODSS 1.9 (0–9) 0
INCAT DS 1.6 (0–8) 0
R-ODS 41.1 (10–48) 48
CDAS, CIDP disease activity status; HFMS, Hammersmith Functional
Motor Scale; INCAT, Inflammatory Neuropathy Cause and
Treatment; INCAT DS, INCAT Disability Score; ISS, INCAT Sensory
Sum Score; MRC, Medical Research Council Sum Score; M-NIS,
motor scores of NIS; NSS, Neurological Symptom Score; ODSS,
Overall Disability Sum Score; R-ODS, Overall Disability Scale; S-NIS,
sensory scores of NIS.
Principal component analysis
Thirteen PCs resulted from the PCA and the PCs
1–5 are shown in Table 4. The first two PCs explained
more than 80% of the variability within the group. The
motor scores, disability scales and CDAS contributed
substantially to the first PC (the linear combination of
the standardized original variables that has the greatest
possible variance) and explained 55% of the variability,
while the disease duration and sensory scores had high
influence in the second PC and accounted for 25%
of the variability. The graphical representation of the
loading plot for these two PCs showed the similarities
of the original variables, creating clusters on the axis
(Fig. 1). CDAS and NIS had major contributions to the
first PC, but also had moderate fractions in the second
PC, while disease duration and S-NIS contributed
moderately to another PC besides the second PC.
Age and NSS did not contribute significantly to the first
two PCs; however, they had moderate input in several
PCs, revealing other components of the clinical picture
besides motor or sensory findings.
Correlation analysis
The correlation analysis demonstrated why the
PCA yielded two main subgroups of grading systems
(Table S1, Supporting Information), with strong
correlations inside the groups of scores and scales
(motor or sensory impairment, disability), between
the motor and disability scores, but not between the
sensory scores and the other groups. Age did not
correlate with any score, while the disease duration
correlated with both of the sensory scores, but none
of the disability or motor impairment scales. As shown
by the PCA, the CDAS correlated with the motor
impairment scores and strongly with the disability
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Table 4. Loading matrix of the first five principal
components.
PC1
(55.7%)
PC2
(25.6%)
PC3
(6.2%)
PC4
(4.3%)
PC5
(3.4%)
CDAS 0.80 −0.39 0.19 −0.15 0.17
Age −0.18 0.63 0.57 −0.46 −0.09
Duration 0.17 0.85 −0.17 0.12 −0.37
ISS 0.06 0.95 −0.06 0.07 0.06
S-NIS 0.13 0.86 −0.08 0.00 0.45
NSS 0.71 0.33 0.42 0.39 −0.07
M-NIS 0.96 −0.01 −0.15 −0.06 0.00
HFMS −0.90 0.07 0.23 0.20 0.07
MRC −0.89 −0.12 0.21 0.25 0.16
NIS 0.87 0.39 −0.12 0.00 0.10
ODSS 0.93 −0.20 0.19 0.04 −0.07
INCAT DS 0.92 −0.21 0.20 0.15 0.01
R-ODS −0.97 0.11 0.02 −0.02 −0.06
The principal component (PC) analysis of the studied scores and
scales showed 13 PCs, with eigenvalue percentages ranging from
55.7% to 0.009%. The first five PCs, with eigenvalue percentages
of >2%, are presented in the table, with the loading factor for
each variable (age and grading systems). Bold values indicate
high component loading values for the variable, while italic values
indicate amedium contribution to the PC. The components that have
major contributions (absolute fractions>0.8) to the first two PCs
clearly form two distinctive subgroups: (1) motor scores, disability
scales and CDAS; and (2) sensory scores and disease duration.
CDAS, CIDP disease activity status; HFMS, Hammersmith Functional
Motor Scale; INCAT, Inflammatory Neuropathy Cause and
Treatment; INCAT DS, INCAT Disability Score; ISS, INCAT Sensory
Sum Score; MRC, Medical Research Council Sum Score; M-NIS,
motor scores of NIS; NSS, Neurological Symptom Score; ODSS,
Overall Disability Sum Score; R-ODS, Overall Disability Scale; S-NIS,
sensory scores of NIS.
scales, but not with the sensory scores, age of
patients, or disease duration.
Discussion
The large spectrum of clinical manifestations is a
hallmark of CIDP. A number of clinical scores and
scales have been proposed to assess the clinical
course and treatment outcome, evaluating several
levels of impairment, disability, or quality of life, and
to estimate the short-term effect of treatment (Dyck
et al., 1982; Mendell et al., 2001; Hughes et al., 2008;
van Schaik et al., 2010). Recently, a disease activity
status scale (CDAS) has been developed that focuses
on the long-term evolution of CIDP (Gorson et al.,
2010).
This study analyzed the relationship between
some of the scores used in clinical practice or research
in order to establish if any of them correlate to the
CDAS. As our cohort did not include cured patients
or patients with normal examination (Gorson et al.,
2010), and in order to make valid comparisons, we
used a modified CDAS where the classes with normal
examination were pooled at zero on the scale (Table 1).
The scales with the most important contributions
to the first two PCs yielded from our PCA form
two clear clusters along the orthogonal axis in
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Figure 1. Loading plot of the first two principal components
(PCs). The PC analysis revealed that the first two PCs
contributed together to more than 80% to the variability
of the group of scores and scales. The two-dimensional
representations of factor loadings of these two PCs shows
clustering along the axis of disability scales (R-ODS, ODSS,
INCAT DS) and motor scores (M-NIS, MRC and HFMS) for
the first PC; and the disease duration and sensory scores
(ISS, S-NIS) for the second PC, describing two distinct
characteristics of the disease. These scores and scales
either do not correlate, or correlate strongly with the CDAS.
The scores evaluating both motor and sensory impairment
(NIS and NSS) form a separate cluster, while age does not
contribute significantly to the first two PCs.
the graphical representation (Fig. 1), delineating two
distinct subgroups: (1) motor scores, disability scales
and CDAS; and (2) sensory scores and disease
duration. The two clusters are virtually perpendicular
and the component variables do not correlate with
each other (Table S1), indicating the possibility that the
subgroups describe different characteristics of CIDP.
The strong correlation between motor scores and the
disability scales confirms the assertion that disability
is mainly due to the motor impairment (Merkies et al.,
2002; van Nes et al., 2011), although this association
was expected as the scales used are designed to
measure primarily the motor deficit.
Age, disease duration, NSS, and NIS supply
notable fractions (>0.25) to more than one PC,
indicating multiple contributions to the variability of
the group and to the phenotype of patients in the
studied cohort (Table 4). NSS and NIS form a third
intermediate cluster on the first diagonal, given that
they evaluate more than one type of deficit (Fig. 1).
Age does not appear to play a role in the disease
manifestations in the studied cohort. It does not cluster
with any scale in the first two PCs, nor correlates
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with any of the motor or general disability grading
systems, and there is only a very slight correlation
with the sensory scores, as reported in other studies
(Merkies et al., 1999) indicating that age does not play
a role in the severity of the disease. In contrast, there
is a clear association between disease duration and
sensory scores (R = 0.63 vs. S-NIS and R = 0.8 vs. ISS),
which is in accordance with our clinical experience,
that even in aggressively treated CIDP patients, the
sensory deficits often persist distally, with or without
neuropathic pain, and may reflect irreversible axonal
loss, but rarely contribute to functional disability.
Comparing the modified CDAS with the evaluated
clinical characteristics and scales, we found that it
correlates strongly with the disability scales and to
a slightly lesser extent with the motor scores, and
that it presents either no or very little association
with age, disease duration or the scores that also
evaluate sensory symptoms. This finding supports
the existence of a link between CDAS, disability and
motor deficit in the studied cohort, while the sensory
impairment has only a minor influence on the CDAS.
Given that CDAS evaluates the disease activity based
on the presence or the follow-up of a treatment, we
can infer that the sensory scales might have a limited
utility when assessing the outcome in CIDP patients
during follow-up and in clinical trials.
Limitations to this study include the size of the
cohort. We also had to normalize some of the nonlinear
variables in order to analyze our data. For clarity, we
presented only the results obtained from the PCA;
however, a complementary analysis using Spearman’s
test for nonparametric data had yielded similar
correlation results. Further, data from nerve conduction
studies were not incorporated in the correlation
analysis due to the variability in the parameters.
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